SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) reporting_unit clinicalTrial segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jan. 01, 2022 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decreased in research and development expenses and related accrued expenses	$ 7,700,000	$ 1,500,000	$ 6,200,000
Number of Phase1/2 clinical trials in process | clinicalTrial		1
Number of Phase 3 clinical trials in process | clinicalTrial		3
Allowance for doubtful accounts	0	$ 0	0
Inventory reserve	3,500,000	3,500,000	4,100,000
Research and development		$ 7,500,000
Number of segments | segment		1
Number of reporting units | reporting_unit		1
Goodwill, impairment		$ 0	0	$ 0
Impairment of intangible assets		0	0	0
Additional paid-in capital	(1,059,975,000)	(1,059,975,000)	(1,068,634,000)
Reduction in accumulated deficit	$ (1,014,223,000)	(1,014,223,000)	(765,966,000)
Foreign currency transaction gain		$ 1,400,000	$ 300,000	$ 1,200,000
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Convertible notes payable					$ 44,700,000
Additional paid-in capital					74,900,000
Reduction in accumulated deficit					$ 30,200,000